Advanced searches left 3/3

Blood Test - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 10 August 2022

* If you want to update the article please login/register

SMARTChip: A Field Deployable Blood Test for Stroke, Capable of Detecting Brain Ischaemia From the Earliest Stages of Pathology

Patients of Stroke will be prospectively accepted to the trial on admission to A&E. As part of their standard therapy, the patient will also be seen for a CT head scan. Following a stroke, a sub-set of patients' blood samples will be taken to obtain insight into how purine levels can change in blood following a stroke. An MRI brain scan will be performed at 24-72 hrs post-admission, and recruitment will continue until 100 patients with MRI measurements have been completed. This investigation is twofold: 1 to determine the variability of blood purines in healthy populations and 2nd to determine whether stroke patients have elevated blood purine levels compared to healthy controls. A baseline blood sample, a simple purine rich meal a meat sandwich, and then four more blood samples are collected at 10, 30, 60, and 120 minutes following the meal will be conducted by Healthy volunteer feeding controls. Patients recruited at University Hospitals North Midlands NHS Trust in the main study will also be able to participate in the Spasticity and Pharmacokinetic sub-studies. Participants in the Spasticity sub-study will obtain an additional blood sample to determine biomarkers and will perform a spasticity examination at admission, 24h, 72h, 7d, and one or two clinic visits between 30-90s post-admission were collected between 30-90s post-admission. At admission, 24h, 72h, 7d, and 30-90th post-admission, participants in the pharmacokinetic subgroup will obtain an additional blood sample for determination of glutamate and other biomarkers.

Source link: https://clinicaltrials.gov/ct2/show/NCT02795481


Discarded Bone Marrow for Hematology Research

Bone marrow transplantation is the only current curative treatment for SCD. Gene therapy and gene editing are particularly popular because they eliminate both the need for donors and the potentially lethal side effects of Graft-versus-Hospital Disease's potentially lethal side effects of Graft-versus-Host Disease because they use the patient's own cells. However, more work remains to be done to create optimal gene therapy and gene editing protocols, as well as better understanding the inherent biology of HSPCs in patients with hemoglobinopathies. St. Jude researchers want to know how to best manipulate HSPCs from hemoglobinopathy patients with gene therapy and gene editing techniques to ensure optimal gene repair and/or replacement, as well as optimal transplantation of transplanted' HSPCs after transplantation. St. Jude researchers are also looking into testing SCD HSPCs on SCD HSPCs in hopes of reducing SCD symptoms. Also, St. Jude researchers continue to investigate the basic biology and function of HSPCs isolated from hemoglobinopathy patients.

Source link: https://clinicaltrials.gov/ct2/show/NCT04671212


Post Market Clinical Utility of ESId (MDW Hematology Parameter) for Early Sepsis Detection in the Emergency Department (US Hospitals) - Indiana University Hospital

This study aims to develop a method for identifying sepsis patients from electronic health records based on Sepsis-2 criteria. Patients of Sepsis will be identified using a Sepsis Definition that includes: meeting a SIRS score of u22652 within 12 hours of ED presentation and any microbial testing performed within 24 hours of ED presentation.

Source link: https://clinicaltrials.gov/ct2/show/NCT04819035


Post Market Clinical Utility of ESId (MDW Hematology Parameter) for Early Sepsis Detection in the Emergency Department (US Hospitals) - Hackensack University Medical Center

Sepsis patients will be identified using a Sepsis Definition that includes a SIRS score of u22652 within 12 hours of ED presentation and any microbial testing performed within 24 hours of ED presentation. In addition, the goals include: to establish the clinical reliability and success of MDW in a control population of sepsis patients in whom MDW is measured but not reported to physicians.

Source link: https://clinicaltrials.gov/ct2/show/NCT04804306

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions